Cargando…
Biomarker-based risk model to predict cardiovascular events in patients with acute coronary syndromes – Results from BIPass registry
BACKGROUND: Risk models integrating new biomarkers to predict cardiovascular events in acute coronary syndromes (ACS) are lacking. Therefore, we evaluated the prognostic value of biomarkers in addition to clinical predictors and developed a biomarker-based risk model for major adverse cardiovascular...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9160492/ https://www.ncbi.nlm.nih.gov/pubmed/35664511 http://dx.doi.org/10.1016/j.lanwpc.2022.100479 |
_version_ | 1784719281057955840 |
---|---|
author | Wang, Jiali Gao, Wei Chen, Guanghui Chen, Ming Wan, Zhi Zheng, Wen Ma, Jingjing Pang, Jiaojiao Wang, Guangmei Wu, Shuo Wang, Shuo Xu, Feng Chew, Derek P. Chen, Yuguo |
author_facet | Wang, Jiali Gao, Wei Chen, Guanghui Chen, Ming Wan, Zhi Zheng, Wen Ma, Jingjing Pang, Jiaojiao Wang, Guangmei Wu, Shuo Wang, Shuo Xu, Feng Chew, Derek P. Chen, Yuguo |
author_sort | Wang, Jiali |
collection | PubMed |
description | BACKGROUND: Risk models integrating new biomarkers to predict cardiovascular events in acute coronary syndromes (ACS) are lacking. Therefore, we evaluated the prognostic value of biomarkers in addition to clinical predictors and developed a biomarker-based risk model for major adverse cardiovascular events (MACE) within 12 months after hospital admission with ACS. METHODS: Patients (n = 4407) consecutively enrolled from November, 2017 to October, 2019 in three hospitals of a prospective Chinese registry (BIomarker-based Prognostic Assessment for Patients with Stable Angina and Acute Coronary Syndromes, BIPass) were designated as the risk model development cohort. Validation was performed in 1409 patients enrolled in two independent hospitals. Cox proportional hazards regression analysis was used to generate a risk prediction model and evaluate the incremental prognostic value of each biomarker. FINDINGS: Over 12 months, 196 patients experienced MACE (5.1%/year). Among twelve candidate biomarkers, N-terminal pro-B-type natriuretic peptide (NT-proBNP) measured at baseline showed the most prognostic capability independent of clinical predictors. The developed BIPass risk model included age, hypertension, previous myocardial infarction, stroke, Killip class, heart rate, and NT-proBNP. It displayed improved discrimination (C-statistic 0.79, 95% CI 0.73-0.85), calibration (GOF = 9.82, p = 0.28) and clinical decision curve in the validation cohort, outperforming the GRACE and TIMI risk scores. Cumulative rates for MACE demonstrated good separation in the BIPass predicted low, intermediate, and high-risk groups. INTERPRETATION: The BIPass risk model, integrating clinical variables and NT-proBNP, is useful for predicting 12-month MACE in ACS. It effectively identifies a gradient risk of cardiovascular events to aid personalized care. FUNDING: National Key R&D Program of China (2017YFC0908700, 2020YFC0846600), National S&T Fundamental Resources Investigation Project (2018FY100600, 2018FY100602), Taishan Pandeng Scholar Program of Shandong Province (tspd20181220), Taishan Young Scholar Program of Shandong Province (tsqn20161065, tsqn201812129), Youth Top-Talent Project of National Ten Thousand Talents Plan and Qilu Young Scholar Program. |
format | Online Article Text |
id | pubmed-9160492 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-91604922022-06-03 Biomarker-based risk model to predict cardiovascular events in patients with acute coronary syndromes – Results from BIPass registry Wang, Jiali Gao, Wei Chen, Guanghui Chen, Ming Wan, Zhi Zheng, Wen Ma, Jingjing Pang, Jiaojiao Wang, Guangmei Wu, Shuo Wang, Shuo Xu, Feng Chew, Derek P. Chen, Yuguo Lancet Reg Health West Pac Articles BACKGROUND: Risk models integrating new biomarkers to predict cardiovascular events in acute coronary syndromes (ACS) are lacking. Therefore, we evaluated the prognostic value of biomarkers in addition to clinical predictors and developed a biomarker-based risk model for major adverse cardiovascular events (MACE) within 12 months after hospital admission with ACS. METHODS: Patients (n = 4407) consecutively enrolled from November, 2017 to October, 2019 in three hospitals of a prospective Chinese registry (BIomarker-based Prognostic Assessment for Patients with Stable Angina and Acute Coronary Syndromes, BIPass) were designated as the risk model development cohort. Validation was performed in 1409 patients enrolled in two independent hospitals. Cox proportional hazards regression analysis was used to generate a risk prediction model and evaluate the incremental prognostic value of each biomarker. FINDINGS: Over 12 months, 196 patients experienced MACE (5.1%/year). Among twelve candidate biomarkers, N-terminal pro-B-type natriuretic peptide (NT-proBNP) measured at baseline showed the most prognostic capability independent of clinical predictors. The developed BIPass risk model included age, hypertension, previous myocardial infarction, stroke, Killip class, heart rate, and NT-proBNP. It displayed improved discrimination (C-statistic 0.79, 95% CI 0.73-0.85), calibration (GOF = 9.82, p = 0.28) and clinical decision curve in the validation cohort, outperforming the GRACE and TIMI risk scores. Cumulative rates for MACE demonstrated good separation in the BIPass predicted low, intermediate, and high-risk groups. INTERPRETATION: The BIPass risk model, integrating clinical variables and NT-proBNP, is useful for predicting 12-month MACE in ACS. It effectively identifies a gradient risk of cardiovascular events to aid personalized care. FUNDING: National Key R&D Program of China (2017YFC0908700, 2020YFC0846600), National S&T Fundamental Resources Investigation Project (2018FY100600, 2018FY100602), Taishan Pandeng Scholar Program of Shandong Province (tspd20181220), Taishan Young Scholar Program of Shandong Province (tsqn20161065, tsqn201812129), Youth Top-Talent Project of National Ten Thousand Talents Plan and Qilu Young Scholar Program. Elsevier 2022-05-30 /pmc/articles/PMC9160492/ /pubmed/35664511 http://dx.doi.org/10.1016/j.lanwpc.2022.100479 Text en © 2022 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Articles Wang, Jiali Gao, Wei Chen, Guanghui Chen, Ming Wan, Zhi Zheng, Wen Ma, Jingjing Pang, Jiaojiao Wang, Guangmei Wu, Shuo Wang, Shuo Xu, Feng Chew, Derek P. Chen, Yuguo Biomarker-based risk model to predict cardiovascular events in patients with acute coronary syndromes – Results from BIPass registry |
title | Biomarker-based risk model to predict cardiovascular events in patients with acute coronary syndromes – Results from BIPass registry |
title_full | Biomarker-based risk model to predict cardiovascular events in patients with acute coronary syndromes – Results from BIPass registry |
title_fullStr | Biomarker-based risk model to predict cardiovascular events in patients with acute coronary syndromes – Results from BIPass registry |
title_full_unstemmed | Biomarker-based risk model to predict cardiovascular events in patients with acute coronary syndromes – Results from BIPass registry |
title_short | Biomarker-based risk model to predict cardiovascular events in patients with acute coronary syndromes – Results from BIPass registry |
title_sort | biomarker-based risk model to predict cardiovascular events in patients with acute coronary syndromes – results from bipass registry |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9160492/ https://www.ncbi.nlm.nih.gov/pubmed/35664511 http://dx.doi.org/10.1016/j.lanwpc.2022.100479 |
work_keys_str_mv | AT wangjiali biomarkerbasedriskmodeltopredictcardiovasculareventsinpatientswithacutecoronarysyndromesresultsfrombipassregistry AT gaowei biomarkerbasedriskmodeltopredictcardiovasculareventsinpatientswithacutecoronarysyndromesresultsfrombipassregistry AT chenguanghui biomarkerbasedriskmodeltopredictcardiovasculareventsinpatientswithacutecoronarysyndromesresultsfrombipassregistry AT chenming biomarkerbasedriskmodeltopredictcardiovasculareventsinpatientswithacutecoronarysyndromesresultsfrombipassregistry AT wanzhi biomarkerbasedriskmodeltopredictcardiovasculareventsinpatientswithacutecoronarysyndromesresultsfrombipassregistry AT zhengwen biomarkerbasedriskmodeltopredictcardiovasculareventsinpatientswithacutecoronarysyndromesresultsfrombipassregistry AT majingjing biomarkerbasedriskmodeltopredictcardiovasculareventsinpatientswithacutecoronarysyndromesresultsfrombipassregistry AT pangjiaojiao biomarkerbasedriskmodeltopredictcardiovasculareventsinpatientswithacutecoronarysyndromesresultsfrombipassregistry AT wangguangmei biomarkerbasedriskmodeltopredictcardiovasculareventsinpatientswithacutecoronarysyndromesresultsfrombipassregistry AT wushuo biomarkerbasedriskmodeltopredictcardiovasculareventsinpatientswithacutecoronarysyndromesresultsfrombipassregistry AT wangshuo biomarkerbasedriskmodeltopredictcardiovasculareventsinpatientswithacutecoronarysyndromesresultsfrombipassregistry AT xufeng biomarkerbasedriskmodeltopredictcardiovasculareventsinpatientswithacutecoronarysyndromesresultsfrombipassregistry AT chewderekp biomarkerbasedriskmodeltopredictcardiovasculareventsinpatientswithacutecoronarysyndromesresultsfrombipassregistry AT chenyuguo biomarkerbasedriskmodeltopredictcardiovasculareventsinpatientswithacutecoronarysyndromesresultsfrombipassregistry AT biomarkerbasedriskmodeltopredictcardiovasculareventsinpatientswithacutecoronarysyndromesresultsfrombipassregistry |